With the increasing incidence of prostate cancer, the effort to improve its diagnostics is also growing. The exclusively used and practice-proven prostate-specific antigen (PSA) continues to play an indispensable role in identifying at-risk patients, but some of its isoforms can also provide important information for deciding the patient's further fate. Based on their combination, a so-called prostate health index (PHI) can be determined. A recently published work by Czech authors assessed the usability of PHI as a parameter suitable for…
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
